Navigation Links
Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting
Date:5/26/2009

MALVERN, Pa., May 26 /PRNewswire/ -- Ascenta Therapeutics announced today that eleven presentations or publications on pre-clinical and clinical studies of AT-101, an oral, pan-Bcl-2 inhibitor, in several major tumor types will be made during the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, in Orlando, Florida. Abstracts are available at www.asco.org.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090227/PH75873LOGO )

Prostate Cancer

MacVicar G, et al. An open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with castrate resistant prostate cancer (CRPC). Abstract #5062; Poster Board #17; Poster Discussion, May 31, 8:00 a.m.-12:00 p.m.

Poiesz B, et al. Preliminary report of an open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with docetaxel refractory prostate cancer. Abstract #5145; Poster Board #J13; GU General Poster Session, May 31, 2:00 p.m.-6:00 p.m.

Glioma

Fiveash J, et al. NABT-0702: A phase II study of AT-101 in recurrent glioblastoma multiforme (GBM). Abstract #2010; Poster Board #2; Poster Discussion, May 30, 8:00 a.m.-12:00 p.m.

Lung Cancer

Heist R, et al. A phase I/II study of AT-101 in combination with topotecan (T) in patients with relapsed or refractory small cell lung cancer (SCLC) after prior platinum containing first line chemotherapy. Abstract #8106; Poster Board #R14; Lung Cancer - Metastatic, May 30, 2:00 p.m.-6:00 p.m.

Ready N, et al. AT-101 or placebo (P) with docetaxel (D) in second line NSCLC with ge
'/>"/>

SOURCE Ascenta Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer
2. Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
3. FDA Accepts Arno Therapeutics IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway
4. Logical Therapeutics Appoints Peter A. Lankau as CEO and Director
5. Arcion Therapeutics Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
6. Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
7. Hyperion Therapeutics Receives Orphan Drug Designation for HPN-100 for the Treatment of Urea Cycle Disorders
8. Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
9. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
10. Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...v.25/PRNewswire/--SwissrayInternational,Inc.aleadi...tems,announcedtodaythatitsoperationshavebeenacquir...rowingSwissray,smedicalimagingbrand.Theacquisition...ontractsandinventory.After25yearsofsuccessandgrowt...gicaladvancementswithstableandsteadygrowth. ,, ...
(Date:11/25/2009)...wire/--Reportlinker.comannouncesthatanewmarketrese...asalDrugDelivery-USMarketTrends&Analysis http...elivery---US-Market-Trends--Analysis.html ,, T...nsionoftherapeuticapplicationsfromthedeliveryofcon...mictherapeuticdrugs.Thefutureofthetechnologyhinges...
(Date:11/24/2009)...ewswire/-- ,, WHAT:RomHoubens,aBelgianmanthough...,wasactuallyfullyconsciousandawakeduringthattimean...VoxEyeMaxwasfeaturedinthesegmenttoillustratehowpeo...kcommunication. ,, WHEN:GoodMorningAmerica-- Tu...ech.com ,, WHO:RomHoubenswasanengineeringst...
Breaking Medicine Technology:Swissray International Announces New Ownership 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2BioNeutrals Ygiene 28TM 29 Hospital Grade Antimicrobial Demonstrates a 99 9997 25 Kill Rate Against Clostridium Difficile Spores 28C diff 29 in Indep 12955 1BioNeutrals Ygiene 28TM 29 Hospital Grade Antimicrobial Demonstrates a 99 9997 25 Kill Rate Against Clostridium Difficile Spores 28C diff 29 in Indep 12955 2BioNeutrals Ygiene 28TM 29 Hospital Grade Antimicrobial Demonstrates a 99 9997 25 Kill Rate Against Clostridium Difficile Spores 28C diff 29 in Indep 12955 3Questions to Pharmacists Rise After Michael Jacksons Death 51194 1Questions to Pharmacists Rise After Michael Jacksons Death 51194 2IDEV Technologies Names Veteran Medical Device Executive Rick Anderson Chairman of the Board of Directors 12952 1IDEV Technologies Names Veteran Medical Device Executive Rick Anderson Chairman of the Board of Directors 12952 2
...loping Embryonic Stem Cell Lines for Therapeutic ...C., Jan. 17 A California research team has,become...the cloning of a,human embryo using donated oocyte...onor. The study was published online today by the ....com/cgi-bin/prnh/20080117/CLTH022LOGO ), The ex...
...Vical Incorporated,(Nasdaq: VICL ) today announce...AnGes MG, Inc. for costs associated with the ongoi...c Melanoma (AIMM) Phase 3 trial., AnGes is fundin...er a,previously announced collaborative agreement ...uity investments totaling $22.6 million, for which...
Other Medicine Technology:Study Reports Successful Cloning of Human Embryo Using Adult DNA 2Study Reports Successful Cloning of Human Embryo Using Adult DNA 3Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial 2Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial 3
(Date:11/25/2009)...RA,Fla.,Nov.25/PRNewswire/--DanielTouizer,CEOof C...teedissuehealthinsurancebenefitprograms,isconcerne...meansnearlyoneinfiveAmericansarewithoutafull-timej...mploymentratesaredeterminedbytheU-6number,whichhas...ani e l T ouizer ."Thesestatisticsarealarming...
(Date:11/25/2009)...e is available in French and Spanish . , ,...ave provided an early diagnosis of certain ocular ...elated macular degeneration and keratitis, by appl...ess, had never before been used for this purpose. ...ge quality in subjects affected by one of these tw...
(Date:11/25/2009)...release is available in French . , , Montrea...e about to enter the marketplace, thanks to a new ...nership (Univalor) and Cognitive Sensing Inc. (CSI...ontreal. , Univalor, which commercializes discov...ated institutions, and CSI have announced the sign...
(Date:11/25/2009)...ruit fly study may lead to new drugs for people, r...ealthDay News) -- Sphingadienes, natural lipid mol... in treatments for colon cancer, California resear...ry, but the study authors pointed out that they co...on against colon cancer. , In the study, Dr. Ju...
(Date:11/25/2009)...fer waistline-friendly ways to enjoy festive feast...ws) -- If you love the five-week holiday smorgasbo...y stressing about the added pounds you,ll have to ...possible, say nutrition experts, to enjoy holiday ...you do today. , It,s all about devising a stra...
Breaking Medicine News(10 mins):Health News:Cinergy Health Commentary on Health Care for the Unemployed 2Health News:Achieve early diagnosis of ocular pathologies such as keratitis and macular degeneration 2Health News:Univalor and Cognitive Sensing Inc. to commercialize 4 University of Montreal discoveries 2Health News:Natural Soy Component May Help Treat Colon Cancer 2Health News:Holiday Eating Without the Guilt -- or the Pounds 2Health News:Holiday Eating Without the Guilt -- or the Pounds 3
...The United Nations has launched a coordinated acti...tive health of women across the globe.// The...UNFPA) comes in the wake of estimates that more th... worrying rise in the number and severity of sexua...
...Hormones do not cause pre-menstrual tension and po...t, according to a leading women's health expert //... Sydney. She wants to bring about a change in the ... than a medical illness. Post-natal depression and...
...Finally there is some scientific research to expla...gs that seem to be said in a perfectly audible vol... what seems like a reasonable volume to them is so...e House Ear Institute in Los Angeles has said that...
...In a move to ensure all NHS patients get the oppor...ernment is introducing a system of random checks /...with the appointment times. The official fig...ents' actual experiences. Critics do argue that th...
...US research have suggested that an electronic devi...rts, explaining that the hand-held device creates ...pts' the migraine. // Researchers have expla...researchers from the UK have cautioned that though...
...The Ontario government is tackling obesity by aimi... to eat their vegetables. // According to Heal...would be launching a pilot project this fall, wher... goal is, if successful, I'd like to see it stretc...
Other Medicine News:Health News:GP's discontented with 48-hour target 2Health News:Researchers Develop An Electric Device For Relief From Migraine 2Health News:Obesity Tackled at School Level 2
Focus Diagnostics
IBT Reference Laboratory
Regional Medical Laboratory
LabOne
Medicine Products: